{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:00:33Z","timestamp":1772805633096,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,7,20]],"date-time":"2013-07-20T00:00:00Z","timestamp":1374278400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s40268-013-0020-x","type":"journal-article","created":{"date-parts":[[2013,7,19]],"date-time":"2013-07-19T12:03:21Z","timestamp":1374235401000},"page":"175-181","source":"Crossref","is-referenced-by-count":14,"title":["Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function"],"prefix":"10.1007","volume":"13","author":[{"given":"Meheroz H.","family":"Rabadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Kreymborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea S.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,7,20]]},"reference":[{"issue":"10","key":"20_CR1","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1517\/14656566.2011.586338","volume":"12","author":"H Panitch","year":"2011","unstructured":"Panitch H, Applebee A. Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability. Expert Opin Pharmacother. 2011;12(10):1511\u201321.","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"20_CR2","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.apmr.2007.07.032","volume":"88","author":"J Paltamaa","year":"2007","unstructured":"Paltamaa J, Sarasoja T, Leskinen E, Wikstr\u00f6m J, M\u00e4lki\u00e4 E. Measures of physical functioning predict self-reported performance in self-care, mobility, and domestic life in ambulatory persons with multiple sclerosis. Arch Phys Med Rehabil. 2007;88(12):1649\u201357.","journal-title":"Arch Phys Med Rehabil"},{"issue":"5","key":"20_CR3","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/1352458506070658","volume":"12","author":"CL Martin","year":"2006","unstructured":"Martin CL, Phillips BA, Kilpatrick TJ, Butzkueven H, Tubridy N, McDonald E, Galea MP. Gait and balance impairment in early multiple sclerosis in the absence of clinical disability. Mult Scler. 2006;12(5):620\u20138.","journal-title":"Mult Scler"},{"issue":"7","key":"20_CR4","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1177\/1352458508088916","volume":"14","author":"C Heesen","year":"2008","unstructured":"Heesen C, B\u00f6hm J, Reich C, Kasper J, Goebel M, Gold SM. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler. 2008;14(7):988\u201391. doi: 10.1177\/1352458508088916 .","journal-title":"Mult Scler"},{"issue":"3","key":"20_CR5","first-page":"183","volume":"36","author":"MM Rodgers","year":"1999","unstructured":"Rodgers MM, Mulcare JA, King DL, Mathews T, Gupta SC, Glaser RM. Gait characteristics of individuals with multiple sclerosis before and after a 6-month aerobic training program. J Rehabil Res Dev. 1999;36(3):183\u20138.","journal-title":"J Rehabil Res Dev"},{"issue":"12","key":"20_CR6","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s12325-009-0082-x","volume":"26","author":"HL Zwibel","year":"2009","unstructured":"Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther. 2009;26(12):1043\u201357. doi: 10.1007\/s12325-009-0082-x .","journal-title":"Adv Ther"},{"issue":"10","key":"20_CR7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2165\/11205910-000000000-00000","volume":"24","author":"CM Chwieduk","year":"2010","unstructured":"Chwieduk CM, Keating GM. Dalfampridine extended release: in multiple sclerosis. CNS Drugs. 2010;24(10):883\u201391.","journal-title":"CNS Drugs"},{"issue":"1","key":"20_CR8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.pharmthera.2005.10.006","volume":"111","author":"SI Judge","year":"2006","unstructured":"Judge SI, Bever CT Jr. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006;111(1):224\u201359.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"20_CR9","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1212\/WNL.38.12.1884","volume":"38","author":"R Kaji","year":"1988","unstructured":"Kaji R, Sumner AJ. Effects of 4-aminopyridine in experimental CNS demyelination. Neurology. 1988;38(12):1884\u20137.","journal-title":"Neurology"},{"issue":"11","key":"20_CR10","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1212\/01.WNL.0000129263.14219.A8","volume":"62","author":"C Mainero","year":"2004","unstructured":"Mainero C, Inghilleri M, Pantano P, Conte A, Lenzi D, Frasca V, Bozzao L, Pozzilli C. Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine. Neurology. 2004;62(11):2044\u201350.","journal-title":"Neurology"},{"issue":"3","key":"20_CR11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0022-510X(83)90145-4","volume":"60","author":"RE Jones","year":"1983","unstructured":"Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci. 1983;60(3):353\u201362.","journal-title":"J Neurol Sci"},{"issue":"1","key":"20_CR12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ana.410210113","volume":"21","author":"D Stefoski","year":"1987","unstructured":"Stefoski D, Davis FA, Faut M, Schauf CL. 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol. 1987;21(1):71\u20137.","journal-title":"Ann Neurol"},{"issue":"6","key":"20_CR13","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.44.6.1054","volume":"44","author":"CT Bever Jr","year":"1994","unstructured":"Bever CT Jr, Young D, Anderson PA, Krumholz A, Conway K, Leslie J, Eddington N, Plaisance KI, Panitch HS, Dhib-Jalbut S, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology. 1994;44(6):1054\u20139.","journal-title":"Neurology"},{"issue":"3","key":"20_CR14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1352458506069538","volume":"13","author":"AD Goodman","year":"2007","unstructured":"Goodman AD, Cohen JA, Cross A, Vollmer T, Rizzo M, Cohen R, Marinucci L, Blight AR. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler. 2007;13(3):357\u201368.","journal-title":"Mult Scler"},{"issue":"2","key":"20_CR15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jnnp.42.2.171","volume":"42","author":"H Lundh","year":"1979","unstructured":"Lundh H, Nilsson O, Ros\u00e9n I. Effects of 4-aminopyridine in myasthenia gravis. J Neurol Neurosurg Psychiatry. 1979;42(2):171\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"20_CR16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3109\/15563658008989978","volume":"16","author":"DA Spyker","year":"1980","unstructured":"Spyker DA, Lynch C, Shabanowitz J, Sinn JA. Poisoning with 4-aminopyridine: report of three cases. Clin Toxicol. 1980;16(4):487\u201397.","journal-title":"Clin Toxicol"},{"issue":"15","key":"20_CR17","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.wnl.0000326213.89576.0e","volume":"71","author":"AD Goodman","year":"2008","unstructured":"Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, Cohen R, Marinucci LN, Blight AR, Fampridine MS-F202 Study Group. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology. 2008;71(15):1134\u201341.","journal-title":"Neurology"},{"issue":"2","key":"20_CR18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ana.410320203","volume":"32","author":"HA Diemen van","year":"1992","unstructured":"van Diemen HA, Polman CH, van Dongen TM, van Loenen AC, Nauta JJ, Taphoorn MJ, van Walbeek HK, Koetsier JC. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol. 1992;32(2):123\u201330.","journal-title":"Ann Neurol"},{"issue":"9665","key":"20_CR19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","volume":"373","author":"AD Goodman","year":"2009","unstructured":"Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR, Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373(9665):732\u20138.","journal-title":"Lancet"},{"key":"20_CR20","doi-asserted-by":"crossref","unstructured":"Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR; MSF204 Investigators. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol. 2010;68(4):494\u2013502. doi: 10.1002\/ana.22240 .","DOI":"10.1002\/ana.22240"},{"issue":"8","key":"20_CR21","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1177\/1352458511403641","volume":"17","author":"JC Kempen","year":"2011","unstructured":"Kempen JC, de Groot V, Knol DL, Polman CH, Lankhorst GJ, Beckerman H. Community walking can be assessed using a 10-metre timed walk test. Mult Scler. 2011;17(8):980\u201390.","journal-title":"Mult Scler"},{"issue":"3","key":"20_CR22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/1352458511420598","volume":"18","author":"D Gijbels","year":"2012","unstructured":"Gijbels D, Dalgas U, Romberg A, de Groot V, Bethoux F, Vaney C, Gebara B, Medina CS, Maam\u00e2gi H, Rasova K, de Noordhout BM, Knuts K, Feys P. Which walking capacity tests to use in multiple sclerosis? A multicentre study providing the basis for a core set. Mult Scler. 2012;18(3):364\u201371.","journal-title":"Mult Scler"},{"issue":"1","key":"20_CR23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2340\/1650197787192530","volume":"19","author":"DT Wade","year":"1987","unstructured":"Wade DT, Wood VA, Heller A, Maggs J, Langton Hewer R. Walking after stroke. Measurement and recovery over the first 3\u00a0months. Scand J Rehabil Med. 1987;19(1):25\u201330.","journal-title":"Scand J Rehabil Med"},{"key":"20_CR24","first-page":"330","volume":"71","author":"RW Bohannon","year":"1990","unstructured":"Bohannon RW, Andrew AW. Correlation of knee extensor muscle torque and spasticity with gait speed in patients with stroke. Arch Phys Med Rehabil. 1990;71:330\u20133.","journal-title":"Arch Phys Med Rehabil"},{"issue":"1","key":"20_CR25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/03790799009166594","volume":"12","author":"FM Collen","year":"1990","unstructured":"Collen FM, Wade DT, Bradshaw CM. Mobility after stroke: reliability of measures of impairment and disability. Int Disabil Stud. 1990;12(1):6\u20139.","journal-title":"Int Disabil Stud"},{"issue":"2","key":"20_CR26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2519\/jospt.1996.24.2.86","volume":"24","author":"RW Bohannon","year":"1996","unstructured":"Bohannon RW, Andrews AW, Thomas MW. Walking speed: reference values and correlates for older adults. J Orthop Sports Phys Ther. 1996;24(2):86\u201390.","journal-title":"J Orthop Sports Phys Ther"},{"key":"20_CR27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1545968304272762","volume":"19","author":"MH Rabadi","year":"2005","unstructured":"Rabadi MH, Blau A. Admission ambulation velocity predicts length of stay and discharge disposition following stroke in an acute rehabilitation hospital. Neurorehabil Neural Repair. 2005;19:20\u20136.","journal-title":"Neurorehabil Neural Repair"},{"issue":"7","key":"20_CR28","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1053\/apmr.2002.33227","volume":"83","author":"SR Lord","year":"2002","unstructured":"Lord SR, Menz HB. Physiologic, psychologic, and health predictors of 6-minute walk performance in older people. Arch Phys Med Rehabil. 2002;83(7):907\u201311.","journal-title":"Arch Phys Med Rehabil"},{"issue":"2","key":"20_CR29","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ptj\/67.2.206","volume":"67","author":"RW Bohannon","year":"1987","unstructured":"Bohannon RW, Smith MB. Inter rater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67(2):206\u20137.","journal-title":"Phys Ther"},{"issue":"9","key":"20_CR30","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/sc.1996.100","volume":"34","author":"BM Haas","year":"1996","unstructured":"Haas BM, Bergstr\u00f6m E, Jamous A, Bennie A. The inter rater reliability of the original and of the modified Ashworth scale for the assessment of spasticity in patients with spinal cord injury. Spinal Cord. 1996;34(9):560\u20134.","journal-title":"Spinal Cord"},{"issue":"3","key":"20_CR31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1191\/0269215503cr610oa","volume":"17","author":"AD Pandyan","year":"2003","unstructured":"Pandyan AD, Price CI, Barnes MP, Johnson GR. A biomechanical investigation into the validity of the modified Ashworth Scale as a measure of elbow spasticity. Clin Rehabil. 2003;17(3):290\u20133.","journal-title":"Clin Rehabil"},{"issue":"1","key":"20_CR32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/ptj\/82.1.25","volume":"82","author":"M Blackburn","year":"2002","unstructured":"Blackburn M, van Vliet P, Mockett SP. Reliability of measurements obtained with the modified Ashworth scale in the lower extremities of people with stroke. Phys Ther. 2002;82(1):25\u201334.","journal-title":"Phys Ther"},{"issue":"5","key":"20_CR33","first-page":"330","volume":"71","author":"RW Bohannon","year":"1990","unstructured":"Bohannon RW, Andrews AW. Correlation of knee extensor muscle torque and spasticity with gait speed in patients with stroke. Arch Phys Med Rehabil. 1990;71(5):330\u20133.","journal-title":"Arch Phys Med Rehabil"},{"issue":"8","key":"20_CR34","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2340\/16501977-0235","volume":"40","author":"T Paternostro-Sluga","year":"2008","unstructured":"Paternostro-Sluga T, Grim-Stieger M, Posch M, Schuhfried O, Vacariu G, Mittermaier C, Bittner C, Fialka-Moser V. Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy. J Rehabil Med. 2008;40(8):665\u201371. doi: 10.2340\/16501977-0235 .","journal-title":"J Rehabil Med"},{"key":"20_CR35","first-page":"11","volume":"2","author":"RW Bohannon","year":"1992","unstructured":"Bohannon RW. Manual muscle testing of the limbs: considerations, limitations, and alternatives. Phys Ther Pract. 1992;2:11\u201321.","journal-title":"Phys Ther Pract"},{"key":"20_CR36","doi-asserted-by":"crossref","unstructured":"Stineman MG, Shea JA, Jette A, et al. The Functional Independence Measure: tests of scaling assumptions, structure, and reliability across 20 diverse impairment categories. Arch Phys Med Rehabil. 1996;77:1101\u20138. doi: 10.1016\/S0003-9993(96)90130-6 .","DOI":"10.1016\/S0003-9993(96)90130-6"},{"key":"20_CR37","doi-asserted-by":"crossref","unstructured":"Stineman MG, Maislin G. Validity of functional independence measure scores. Scand J Rehabil Med. 2000;32(3):143\u20134. doi: 10.1080\/003655000750045505 .","DOI":"10.1080\/003655000750045505"},{"key":"20_CR38","doi-asserted-by":"crossref","unstructured":"Dodds TA, Martin DP, Stolov WC, Deyo RA. A validation of the functional independence measurement and its performance among rehabilitation inpatients. Arch Phys Med Rehabil. 1993;74:531\u20136. doi: 10.1016\/0003-9993(93)90119-U .","DOI":"10.1016\/0003-9993(93)90119-U"},{"key":"20_CR39","unstructured":"Granger CV. The emerging science of functional assessment: our tool for outcomes analysis. Arch Phys Med Rehabil. 1998;79:235\u201340. doi: 10.1016\/S003-9993(98)9000-4 ."},{"issue":"2","key":"20_CR40","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/1352458506070667","volume":"13","author":"A Cr\u00e9ange","year":"2007","unstructured":"Cr\u00e9ange A, Serre I, Levasseur M, Audry D, Nineb A, Bo\u00ebrio D, Moreau T, Maison P, R\u00e9seau SINDEFI-SEP. Walking capacities in multiple sclerosis measured by global positioning system odometer. Mult Scler. 2007;13(2):220\u20133.","journal-title":"Mult Scler"},{"issue":"9","key":"20_CR41","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1212\/01.wnl.0000256037.63832.6f","volume":"68","author":"MC Fahey","year":"2007","unstructured":"Fahey MC, Corben LA, Collins V, Churchyard AJ, Delatycki MB. The 25-foot walk velocity accurately measures real world ambulation in Friedreich ataxia. Neurology. 2007;68(9):705\u20136.","journal-title":"Neurology"},{"issue":"1","key":"20_CR42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1185\/03007995.2011.639752","volume":"28","author":"CI Coleman","year":"2012","unstructured":"Coleman CI, Sobieraj DM, Marinucci LN. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis. Curr Med Res Opin. 2012;28(1):49\u201356. doi: 10.1185\/03007995.2011.639752 .","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"20_CR43","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/135245850000600411","volume":"6","author":"M Kaufman","year":"2000","unstructured":"Kaufman M, Moyer D, Norton J. The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite. Mult Scler. 2000;6(4):286\u201390.","journal-title":"Mult Scler"},{"issue":"8","key":"20_CR44","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1212\/WNL.58.8.1294","volume":"58","author":"SR Schwid","year":"2002","unstructured":"Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD. Quantitative functional measures in MS: what is a reliable change? Neurology. 2002;58(8):1294\u20136.","journal-title":"Neurology"},{"issue":"1","key":"20_CR45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.apmr.2005.08.130","volume":"87","author":"M Beninato","year":"2006","unstructured":"Beninato M, Gill-Body KM, Salles S, Stark PC, Black-Schaffer RM, Stein J. Determination of the minimal clinically important difference in the FIM instrument in patients with stroke. Arch Phys Med Rehabil. 2006;87(1):32\u20139.","journal-title":"Arch Phys Med Rehabil"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-013-0020-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-013-0020-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-013-0020-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T09:47:34Z","timestamp":1688377654000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-013-0020-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,20]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["20"],"URL":"https:\/\/doi.org\/10.1007\/s40268-013-0020-x","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,20]]}}}